Erbitux for Left Sided Metastatic Colorectal Cancer – Details


( Last Updated : April 26, 2018)
Generic Name:
Cetuximab
Project Status:
Cancelled
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Erbitux
Project Line:
Reimbursement Review
Project Number:
PC0128-000
NOC Date:

Details

Strength:
2 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Left Sided Metastatic Colorectal Cancer
Funding Request:
For the first-line treatment of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours
Review Status:
Cancelled
Sponsor:
Eli Lilly Canada Inc.
Clarification:
The submitter notified pCODR that they will not be filing the submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.